Original article
The drug therapy for type 2 diabetes mellitus is being put to the test again with the stock market call on April 1, 2013. As early as 2011, every second euro of oral antidiabetic drugs (OADs) was spent on DPP-IV inhibitors (cf. Bensing/Kleinfeld 2012), and this share has now increased to almost 63 percent. The significant increases in expenditure (according to list prices) for OAD tend to be offset by constant prescription quantities.
28.05.2013
Opportunities through telematics for patient self-control (TzP) arise first and foremost for the patient. However, before we talk about the benefits of TzP for patients, we should briefly clarify what such benefits can actually consist of. Patients are sick by definition, so one benefit category is: less illness due to TtP, or – according to the Brockhaus definition of illness – fewer disorders of physical, mental and social well-being. But patients are also citizens and especially insured people, so there is a different category of benefits: lower costs for health and disease treatment, lower or less rapidly rising health insurance contributions.
28.05.2013
Gerhard Stein, board member and deputy chairman of the Deutsche BKK since October 2011, also worked for health insurance companies for some time as a human resources manager in clinics in southern Germany: He therefore knows the inpatient system and how it works when he says very carefully that the DRG The system is certainly complicated, but the service providers are trying to optimize the income side. A pension fund like Deutsche BKK, which with its high proportion of pensioners is not exactly one of the winners of the M-RSA system, is basically trying to do something similar - on both the income and expenditure side, which is why its central demand is: “The M-RSA must better reflect the real supply.”
28.05.2013
In addition to the majority of patients with type 1 diabetes, patients with more complex type 2 diabetes, patients with diabetic foot syndrome and pregnant patients with pre-existing diabetes or gestational diabetes are now also treated and trained in diabetology-focused practices (DSPs). In order to gain knowledge about the processes and results, a scientific institute for diabetology in private practice called winDiab was founded by diabetologists themselves five years ago. Since then, a number of concrete and practice-relevant questions have been examined specifically for this level of care and these evaluations, spots, annual reports and registers have been carried out by more than 100 DSPs with almost 160 diabetologists and their teams in their everyday practice. The results have a direct impact on the practical work of DSPs because they are used in communication with payers and lead to changes in the positioning of DSPs in the diabetological scene. In the future, winDiab's work will continue to contribute to ensuring that the necessary range of diagnostic and therapeutic options remains available for the treatment of patients. This article summarizes the work of winDiab and the most important results of the studies carried out over the last five years. At the same time, it is a description of the position of the DSPs and shows how their contribution can be to the scientific development of diabetology.
28.05.2013
Dr. Nikolaus Scheper is a general practitioner, board member of the Federal Association of Resident Diabetologists in Germany (BVND) and founding partner of the non-profit Scientific Institute of Resident Diabetologists (windiab). He is co-owner of the practice Drs. Scheper & Schneider in Marl and is a member of the “Marler Ärztenetz” (MAN) as well as a member of the “Pro-Gesund” network of the Federal Miners’ Association. His practice is also an academic teaching practice at the Ruhr University Bochum.
28.05.2013
Prof. Dr. Bertram Häussler compiled and presented the "Drug Atlas" on behalf of the vfa (Association of German Pharmaceutical Manufacturers), which also addresses innovations. In 2002, Häussler was appointed honorary professor at the Technical University of Berlin, where he teaches "Economics of the Pharmaceutical Industry." He has been managing director of the IGES Institute, Berlin, since 1990 and chairman of the board since 2006.
28.05.2013
Prof. Dr. Gerd Glaeske recently published the TK Innovation Report, which takes a decisive stance on innovations. Glaeske has been a professor of drug application research at the Center for Social Policy at the University of Bremen since 1999, head of the Drug Advice and Drug Information research unit, and co-head of the Department of Health Economics, Health Policy, and Health Services Research at the Center for Social Policy (ZeS) at the University of Bremen since 2007. He is also a member of the MVF scientific advisory board.
28.05.2013
What does a mail-order pharmacy like DocMorris have to do with health services research? More than you might think, as Prof. Dr. rer.nat. Christian Franken, the chief pharmacist at DocMorris, explains in an interview with “Monitor Healthcare Research”. Because the mail order pharmacy, which operates from the Netherlands, has a big advantage: over 2 million patient histories!
28.05.2013
As a current analysis by the information service provider INSIGHT Health shows, there are regional differences in the medication provided to children and adolescents with attention deficit hyperactivity disorder, or ADHD for short. The ADHD stronghold in terms of daily therapy doses (DDD) per capita is Lower Franconia.
28.05.2013
Prof. Dr. Eberhard Wille, the deputy chairman of the Advisory Council for the Assessment of Developments in the Health Care System, prepared a report on behalf of the German Society for Integrated Care in the Health Care System (DGIV). His conclusion: There are definitely options, but also obstacles that stand in the way of a goal-oriented integration of DMP with integrated forms of care; although - status today - the latter seem to predominate.